EA201991004A1 - METHOD FOR TREATING GLYCOGEN ACCUMULATION DISEASE - Google Patents

METHOD FOR TREATING GLYCOGEN ACCUMULATION DISEASE

Info

Publication number
EA201991004A1
EA201991004A1 EA201991004A EA201991004A EA201991004A1 EA 201991004 A1 EA201991004 A1 EA 201991004A1 EA 201991004 A EA201991004 A EA 201991004A EA 201991004 A EA201991004 A EA 201991004A EA 201991004 A1 EA201991004 A1 EA 201991004A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glycogen accumulation
liver
bng
useful
accumulation disease
Prior art date
Application number
EA201991004A
Other languages
Russian (ru)
Inventor
Брайан Лиан
Original Assignee
Вайкинг Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вайкинг Терапьютикс, Инк. filed Critical Вайкинг Терапьютикс, Инк.
Priority claimed from PCT/US2017/062393 external-priority patent/WO2018094265A2/en
Publication of EA201991004A1 publication Critical patent/EA201991004A1/en

Links

Abstract

Настоящее изобретение обеспечивает способы и композиции для лечения симптомов со стороны печени болезней накопления гликогена путем введения агонистов тиреоидных гормонов. Способы и композиции, предложенные в настоящем документе, полезны в лечении гиперлипидемии, гиперхолестеринемии, стеатоза печени, кардиомегалии, гепатомегалии, фиброза печени и цирроза, ассоциированных с болезнями накопления гликогена (БНГ) и дефектами метаболизма гликогена. Указанные соединения также могут быть полезны в предотвращении связанных с БНГ гепатоцеллюлярной аденомы и гепатоцеллюлярной карциномы.The present invention provides methods and compositions for treating symptoms of liver diseases of glycogen accumulation by administration of thyroid hormone agonists. The methods and compositions provided herein are useful in the treatment of hyperlipidemia, hypercholesterolemia, liver steatosis, cardiomegaly, hepatomegaly, liver fibrosis and cirrhosis associated with glycogen accumulation diseases (BNG) and glycogen metabolism defects. These compounds may also be useful in preventing BNG-related hepatocellular adenoma and hepatocellular carcinoma.

EA201991004A 2017-02-08 2017-11-17 METHOD FOR TREATING GLYCOGEN ACCUMULATION DISEASE EA201991004A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762456610P 2017-02-08 2017-02-08
PCT/US2017/062393 WO2018094265A2 (en) 2016-11-21 2017-11-17 Method of treating glycogen storage disease

Publications (1)

Publication Number Publication Date
EA201991004A1 true EA201991004A1 (en) 2019-12-30

Family

ID=69061860

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991004A EA201991004A1 (en) 2017-02-08 2017-11-17 METHOD FOR TREATING GLYCOGEN ACCUMULATION DISEASE

Country Status (1)

Country Link
EA (1) EA201991004A1 (en)

Similar Documents

Publication Publication Date Title
MX2019005730A (en) Method of treating glycogen storage disease.
PH12017502359B1 (en) Glucagon and glp-1 co-agonist compounds
EA201790124A1 (en) SALT BERBERIN, SALT URSODEZOXYCHOLEIC ACID AND THEIR COMBINATION, METHODS OF OBTAINING AND APPLICATION
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
EA201391262A1 (en) COMPOSITION, METHOD OF TREATMENT AND DIAGNOSTICS OF LIVER STEATOSIS AS AN INDEPENDENT DISEASE OR IN COMBINATION WITH HEPATITIS C INFECTION
JOP20200137A1 (en) Incretin analogs and uses thereof
CR20200256A (en) Incretin analogs and uses thereof
MX2021011949A (en) Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy.
NZ746950A (en) Heterocyclic gpr119 agonist compounds
NZ724057A (en) Treatment of intrahepatic cholestatic diseases
MX2021000154A (en) Methods of treating liver fibrosis using calpain inhibitors.
MX2021002305A (en) Treating liver disorders.
MX2016010447A (en) Compositions and methods for treating diabetes and liver diseases.
MX2020007167A (en) Compositions and methods for treating metabolic diseases.
IL276097A (en) Methods for treating diabetes, hepatitis, and/or inflammatory liver disease
BR112018000771A2 (en) antibodies that bind to sortilin and inhibit progranulin binding, pharmaceutical compositions, preparations thereof, use of antibodies, kit and method for preventing or treating a disease associated with decreased levels of pgrn
IL292221A (en) Compositions and methods for treating liver disease
MX2021002655A (en) Combination therapy for the treatment of liver disease.
ZA202001568B (en) Methods and compositions for treating chronic lung diseases
MY184876A (en) Pharmaceutical composition for preventing cccdna formation of hepatitis b virus
EA202190481A1 (en) TRIPEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISEASES
MX2016010699A (en) Compositions and methods for treating neutropenia.
MX2019002579A (en) Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver.
EA201991004A1 (en) METHOD FOR TREATING GLYCOGEN ACCUMULATION DISEASE
EA201990443A1 (en) NEW APPLICATION OF N, N-BIS-2 -MERCAPTOETHYLISOPHTHALAMIDE